These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 21114867

  • 1. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, Kim YH, Mio T, Mishima M, Katakami N.
    BMC Med Genet; 2010 Nov 30; 11():167. PubMed ID: 21114867
    [Abstract] [Full Text] [Related]

  • 2. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.
    Clin Lung Cancer; 2013 Jul 30; 14(4):433-9. PubMed ID: 23522953
    [Abstract] [Full Text] [Related]

  • 3. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S, Zhou S, Zhang L, Xu J, Lv M, Zhang J, Zhou C, Zhang J.
    Cancer Invest; 2010 Dec 30; 28(10):1078-83. PubMed ID: 20504223
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Liu L, Zhou F, Ren S, Chen X, Li X, Li W, Zhou C.
    Asia Pac J Clin Oncol; 2016 Jun 30; 12(2):e339-46. PubMed ID: 25131817
    [Abstract] [Full Text] [Related]

  • 5. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
    Jiang YH, Xu XL, Ruan HH, Xu WZ, Li D, Feng JG, Han QB, Mao WM.
    Med Oncol; 2014 May 30; 31(5):959. PubMed ID: 24722796
    [Abstract] [Full Text] [Related]

  • 6. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ.
    Asian Pac J Cancer Prev; 2012 May 30; 13(5):2157-62. PubMed ID: 22901187
    [Abstract] [Full Text] [Related]

  • 7. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y, Wang D.
    Int J Cancer; 2014 Dec 01; 135(11):2687-96. PubMed ID: 24729390
    [Abstract] [Full Text] [Related]

  • 8. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
    Natukula K, Jamil K, Pingali UR, Suresh Attili VS, Naidu Madireddy UR.
    Asian Pac J Cancer Prev; 2013 Dec 01; 14(8):4661-6. PubMed ID: 24083721
    [Abstract] [Full Text] [Related]

  • 9. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M, Ramirez JL, de Aguirre I, Garrido P, Pérez Cano M, Queralt C, Gonzalez-Larriba JL, Insa A, Provencio M, Isla D, Camps C, Blanco R, Moran T, Rosell R, Spanish Lung Cancer Group.
    Clin Lung Cancer; 2017 Mar 01; 18(2):178-188.e4. PubMed ID: 27908619
    [Abstract] [Full Text] [Related]

  • 10. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.
    Lancet Oncol; 2008 Dec 01; 9(12):1135-42. PubMed ID: 19013107
    [Abstract] [Full Text] [Related]

  • 11. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
    Kim SH, Kim MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY, Ling H, Lee GW.
    Am J Clin Oncol; 2015 Jun 01; 38(3):294-9. PubMed ID: 23689644
    [Abstract] [Full Text] [Related]

  • 12. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X, Shao M, Wang S, Zhao X, Chen H, Qian J, Song X, Wang J, Jin L, Wu J, Li Q, Bai C, Han B, Gao Z, Lu D.
    Tumour Biol; 2014 Nov 01; 35(11):11159-70. PubMed ID: 25104092
    [Abstract] [Full Text] [Related]

  • 13. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D, Neyns B, Fontaine C, Steene JV, De Mey J, Meysman M, De Grève J.
    Lung Cancer; 2007 May 01; 56(2):247-54. PubMed ID: 17337086
    [Abstract] [Full Text] [Related]

  • 14. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
    Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C.
    Lung Cancer; 2012 Jan 01; 75(1):102-9. PubMed ID: 21676483
    [Abstract] [Full Text] [Related]

  • 15. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
    Chen X, Zhang L, Ren S, Li X, Zhou F, Li W, Gao G, He Y, Zhou C.
    Med Oncol; 2014 Apr 01; 31(4):865. PubMed ID: 24535606
    [Abstract] [Full Text] [Related]

  • 16. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH.
    Cancer; 2012 May 01; 118(9):2466-75. PubMed ID: 22031394
    [Abstract] [Full Text] [Related]

  • 17. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
    Liu D, Xu W, Zhang ZW, Qian J, Zheng H, Zhang J, Su B.
    Asian Pac J Cancer Prev; 2015 May 01; 16(2):775-81. PubMed ID: 25684524
    [Abstract] [Full Text] [Related]

  • 18. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
    Lv C, Ma Y, Wu N, Yan S, Zheng Q, Sun Y, Li S, Fang J, Yang Y.
    World J Surg Oncol; 2013 Mar 21; 11():76. PubMed ID: 23517534
    [Abstract] [Full Text] [Related]

  • 19. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
    Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B, Intergroupe Francophone de Cancérologie Thoracique.
    Lancet; 2011 Sep 17; 378(9796):1079-88. PubMed ID: 21831418
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J, Sharma DB, Chen AB, Johnson BE, Weeks JC, Schrag D.
    Cancer; 2013 Jun 01; 119(11):2048-60. PubMed ID: 23564469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.